Who are lidocaine and sufentanil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bupivacaine with hydromorphone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lidocaine-and-sufentanil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

lidocaine and sufentanil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lidocaine and sufentanil (lidocaine and sufentanil) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic and opioid analgesic combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic and opioid analgesic combination Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil) Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

lidocaine and sufentanil (lidocaine and sufentanil) — RenJi Hospital. Lidocaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu opioid receptors to provide analgesia and sedation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lidocaine and sufentanil TARGET	lidocaine and sufentanil	RenJi Hospital	marketed	Local anesthetic and opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)
bupivacaine with hydromorphone	bupivacaine with hydromorphone	University of Virginia	phase 3	Local anesthetic and opioid analgesic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic and opioid analgesic combination class)

RenJi Hospital · 1 drug in this class
University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lidocaine and sufentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-and-sufentanil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab